Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies

Cariad Chester, Miguel F. Sanmamed, Jun Wang, Ignacio Melero

Blood (2018) 131 (1): 49–57.

https://doi.org/10.1182/blood-2017-06-741041

Published: 2018

Journal Articles

Natural Killer Cells Activated By Oncolytic Reovirus Enhance Cetuximab Mediated Antibody Dependent Cellular Cytotoxicity in an in Vitro and In Vivo Model of Colorectal Cancer

Xing Zhao, PhD, Narendiran Rajasekaran, PhD, Cariad Chester, BA, Atsushi Yonezawa, PhD, Suparna Dutt, PhD, Matt Coffey, Zhixu He, MDPhD, Holbrook E Kohrt, MD PhD

Blood (2015) 126 (23): 3439.

https://doi.org/10.1182/blood.V126.23.3439.3439

Published: 2015

Journal Articles

Three BTK-Specific Inhibitors, in Contrast to Ibrutinib, Do Not Antagonize Rituximab-Dependent NK-Cell Mediated Cytotoxicity

Narendiran Rajasekaran, PhDMSc, Mohith Sadaram, BS, Jonathan Hebb, MD, Idit Sagiv-Barfi, PhD, Sid Ambulkar, Amanda Rajapaksa, Serena Chang, PhD, Cariad Chester, Erin Waller, Lai Wang, PhD, Brian Lannutti, PhD, Dave Johnson, Ron Levy, MD, Holbrook E Kohrt, MD PhD

Blood (2014) 124 (21): 3118.

https://doi.org/10.1182/blood.V124.21.3118.3118

Published: 2014

Journal Articles

Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma

Holbrook E Kohrt, MD PhD, Jaqueline Chu, MD, Joshua Brody, MD, Debra K Czerwinski, Cariad Chester, Mohith Sadaram, BS, Ranjana Advani, MD, Youn H. Kim, MD, Richard T. Hoppe, MD, Susan J. Knox, MD PhD, Irene Wapnir, MD, Robert J. Tibshirani, PhD, Ron Levy, MD

Blood (2014) 124 (21): 3092.

https://doi.org/10.1182/blood.V124.21.3092.3092

Published: 2014

Journal Articles

Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo

Sylvia Herter, PhD, Idit Sagiv-Barfi, PhD, Cariad Chester, Mohith Sadaram, BS, Jonathan Hebb, MD, Debra K Czerwinski, Narendiran Rajasekaran, PhDMSc, Marina Bacac, PhD, Pablo Umana, PhD, Ron Levy, MD, Christian Klein, PhD, Holbrook E Kohrt, MD PhD

Blood (2014) 124 (21): 1765.

https://doi.org/10.1182/blood.V124.21.1765.1765

Published: 2014

NARROW

Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies

Natural Killer Cells Activated By Oncolytic Reovirus Enhance Cetuximab Mediated Antibody Dependent Cellular Cytotoxicity in an in Vitro and In Vivo Model of Colorectal Cancer

Three BTK-Specific Inhibitors, in Contrast to Ibrutinib, Do Not Antagonize Rituximab-Dependent NK-Cell Mediated Cytotoxicity

Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma

Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo

Email alerts

ASH Publications

American Society of Hematology

Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies

Natural Killer Cells Activated By Oncolytic Reovirus Enhance Cetuximab Mediated Antibody Dependent Cellular Cytotoxicity in an in Vitro and In Vivo Model of Colorectal Cancer

Three BTK-Specific Inhibitors, in Contrast to Ibrutinib, Do Not Antagonize Rituximab-Dependent NK-Cell Mediated Cytotoxicity

Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma

Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only